Tag: Akero Therapeutics (AKRO)
Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients
Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...
Read More
July 1, 2020
0
Prohost Biotech's Decision About Akero Therapeutics
Akero Therapeutics Today we posted good news from Akero Therapeutics ( AKRO ) under News & Comments . The news was about results from Phase 2a BALANCED study of the firm’s product efruxifermin (EFX), for patients with nonalcoholic steatohepatitis (...
Read More
July 1, 2020
0
Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients
Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...
Read More
July 1, 2020
0
Prohost Biotech's Decision About Akero Therapeutics
Akero Therapeutics Today we posted good news from Akero Therapeutics ( AKRO ) under News & Comments . The news was about results from Phase 2a BALANCED study of the firm’s product efruxifermin (EFX), for patients with nonalcoholic steatohepatitis (...
Read More
July 1, 2020
0
Prohost Letter #444
Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the...
Read More
March 8, 2021
0
Prohost Letter #444
Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio stocks’ targets for the year failed to materialize; nobody not even the authorities were capable of predicting the pandemic, which continues to plague the...
Read More
March 8, 2021
0
Important News and Results from Two Companies in the Prohost Portfolio
Important News and Results from Akero Therapeutics Akero Therapeutics ( AKRO ) announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The study...
Read More
July 9, 2021
0
Akero Therapeutics Inc Q2 Business Updates and Financial Results
Akero Therapeutics Inc Akero Therapeutics Inc ( AKRO ) is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis ( NASH ), a disease without any approved therapies. Akero’s investigational drug product candidate, efruxifermin ( EFX ), is a...
Read More
August 13, 2021
0
Comprehensive Prohost Letter Issues
The Comprehensive Prohost Letter Issues The Comprehensive Prohost Letter Issues will constitute a chain of 7 issues. Today’s issue will include the following: Pinpointing and selecting the biotech firms that demonstrate readiness to treat untreatable, devastating diseases. Presenting an important...
Read More
September 19, 2021
0
Akero Therapeutics' Product Efruxifermin Demonstrates Strong Positive Results in NASH Patients
Akero Therapeutics Efruxifermin Positive Results in NASH Akero Therapeutics ( AKRO ) results of a 16-week analysis of secondary and exploratory endpoints in Phase 2a BALANCED study of its product efruxifermin ( EFX ), formerly known as AKR-001, in patients with...
Read More
July 1, 2020
0
Search ProhostBiotech
Popular Links
23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)